CIViC Compass
Research use only — not FDA-cleared, not medical advice. Always consult FDA-approved labeling and a qualified clinician.

CIViC Evidence Items

21 evidence items indexed

Evidence Level Distribution

CIViC evidence levels reflect study design quality, from A (strongest) to E (weakest).

AValidated — meta-analysis, systematic review, or major guideline
BClinical — prospective trial or retrospective cohort study
CCase study — single case report or small case series
DPreclinical — in vitro or animal model data
EInferential — computational prediction or biological rationale

Gene × Evidence Type

Count of CIViC evidence items per gene and evidence type category. Hover a column header for the type definition.

PredictiveDiagnosticPrognosticFunctionalPredispos.Oncogenic
BCR::ABL132311
BRAF18642621
EGFR2481232
EML4::ALK64
ERBB21422
FLT355221
KIT10237
KRAS1594244
PIK3CA156164
PTEN5313121
TP5352401002
VHL52363515
Predictive:Links a variant to treatment response or resistance
Diagnostic:Supports or refutes a specific disease diagnosis
Prognostic:Informs disease progression or clinical outcome
Functional:Characterises the biological effect of a variant
Predisposing:Germline variant associated with cancer predisposition
Oncogenic:Characterises the variant's role in oncogenesis
Clear
LevelGeneVariantTypeDirectionSignificanceDiseaseDrugsSource
BIDH2R172PrognosticSupportsBetter OutcomeGlioblastomaYan et al., 2009
BIDH2R172PrognosticSupportsBetter OutcomeMalignant AstrocytomaYan et al., 2009
AIDH2R172K OR IDH2 R172G OR IDH2 R172WPredictiveSupportsSensitivity/ResponseLow Grade GliomaVorasidenibMellinghoff et al., 2023
BIDH2R172DiagnosticSupportsPositivePeripheral T-cell LymphomaCairns et al., 2012
BIDH2R172PrognosticSupportsBetter OutcomeAcute Myeloid LeukemiaPapaemmanuil et al., 2016
DIDH2MutationPredictiveSupportsSensitivity/ResponseAcute Myeloid LeukemiaEnasidenibYen et al., 2017
AIDH2MutationPredictiveSupportsSensitivity/ResponseAcute Myeloid LeukemiaEnasidenibStein et al., 2017
BIDH2MutationPrognosticSupportsBetter OutcomeChondrosarcomaZhu et al., 2020
AIDH2Mutation OR IDH1 MutationPredictiveSupportsSensitivity/ResponseGliomaVorasidenibMellinghoff et al., 2023
BIDH2MutationPrognosticDoes Not SupportAcute Myeloid LeukemiaThol et al., 2010
BIDH2R140PrognosticDoes Not SupportMyelodysplastic SyndromePatnaik et al., 2012
BIDH2R140PrognosticSupportsBetter OutcomeAcute Myeloid LeukemiaGreen et al., 2011
BIDH2R172KPrognosticSupportsPoor OutcomeAcute Myeloid LeukemiaGreen et al., 2011
BIDH2R172PrognosticDoes Not SupportBetter OutcomePeripheral T-cell LymphomaWang et al., 2015
BIDH2MutationPrognosticSupportsBetter OutcomeBrain Glioma2015, N. Engl. J. Med.
CIDH2MutationPredictiveSupportsSensitivity/ResponseAcute Myeloid LeukemiaVenetoclaxHuemer et al., 2019
BIDH2R140PrognosticDoes Not SupportAcute Myeloid LeukemiaZhou et al., 2012
BIDH2R140PrognosticDoes Not SupportMyelodysplastic SyndromeLin et al., 2012
BIDH2R172KPrognosticDoes Not SupportAcute Myeloid LeukemiaZhou et al., 2012
BIDH2R172KPrognosticDoes Not SupportMyelodysplastic SyndromeLin et al., 2012
BIDH2R140PrognosticDoes Not SupportAcute Myeloid LeukemiaLin et al., 2012